SCHEMBL2904833

SCHEMBL2904833

Cc1ccc2oc3cc(C(=O)O)c(N)nc3c(=O)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.56
▸ NPC1 O15118 4/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ PKM P14618 2/20 0.56
▸ HPGD P15428 2/20 0.56
▸ TBK1 Q9UHD2 16/20 0.51
▸ IKBKE Q14164 10/20 0.51
▸ ABCC4 O15439 1/20 0.51
▸ TTR P02766 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ ADRA1A P35348 1/20 0.51
▸ OPRD1 P41143 1/20 0.51
▸ PDE4D Q08499 1/20 0.51
▸ PDE3A Q14432 1/20 0.51
▸ GPR35 Q9HC97 1/20 0.51
▸ MAPT P10636 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11548704 0.89 NPC1 (0.57) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2907889 0.85 TTR (0.54) KDM4ENPC1RAB9AALDH1A1PKM
SCHEMBL11406353 0.85 NPC1 (0.56) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL11354810 0.85 RAB9A (0.60) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2910718 0.84 KDM4E (0.55) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2901850 0.84 TBK1 (0.72) KDM4ENPC1RAB9APKMTBK1
SCHEMBL11544885 0.84 TBK1 (0.72) KDM4ENPC1RAB9APKMTBK1
SCHEMBL2907432 0.84 TBK1 (0.56) KDM4ENPC1RAB9APKMTBK1
SCHEMBL2907061 0.84 TTR (0.53) KDM4ENPC1RAB9AALDH1A1PKM
SCHEMBL2907068 0.84 TTR (0.53) KDM4ENPC1RAB9AALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4143042-A ANTIALLERGENS, BRONCHODILATOR AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1979-03-06 — — US claimed
EP-1968981-B1 AZAXANTHONES AND USE THEREOF FOR TREATING TUMORS SUPRATEK PHARMA INC (CA) 2010-08-18 — — EP disclosed
US-7772255-B2 Method of treating tumors with azaxanthones SUPRATEK PHARMA, INC. (CA) 2010-08-10 — — US disclosed
US-20090042923-A1 Method of Treating Tumors with Azaxanthones SEMOV ALEXANDRE 2009-02-12 — — US disclosed
US-20070135473-A1 Method of treating tumors with azaxanthones SUPRATEK PHARMA, INC. 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135473-A1 Method of treating tumors with azaxanthones S100A4, S100B, S100P KDM4E 1501/4885NPC1 4456/4885RAB9A 2400/4885
US-20090042923-A1 Method of Treating Tumors with Azaxanthones S100A4, S100P, S100B KDM4E 1807/4885NPC1 4429/4885RAB9A 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback